Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIUTENSEN-R is a fixed-dose combination oral tablet containing methyclothiazide (a thiazide diuretic) and reserpine (an antihypertensive agent). This product is indicated for the management of hypertension by combining diuretic and sympatholytic mechanisms to reduce blood pressure.
Pre-Launch
Pre-launch status indicates limited current commercial activity; career opportunities will depend on successful market entry and adoption in a mature hypertension category.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DIUTENSEN-R at Bausch Health in its pre-launch phase offers career opportunity in a controlled market entry for an established hypertension therapy. Career impact will be moderate, as the product operates in a mature, competitive category with limited breakthrough potential but stable long-term demand.
Brand ManagerSales Representative
Worked on DIUTENSEN-R at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.